STAAR Surgical Celebrates Three Million Implantable Collamer® Lenses
March 18 2024 - 7:00AM
Business Wire
STAAR Surgical Company (NASDAQ: STAA), a leading developer,
manufacturer and marketer of the EVO family of Implantable
Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia,
today announced that more than three million ICLs have been sold
globally.1
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240318771746/en/
(Graphic: STAAR Surgical)
“We extend our sincere gratitude to the surgeons and clinicians
with whom we partner and to their patients who have chosen our ICLs
for their vision correction as we celebrate our three million lens
milestone,” said Tom Frinzi, President and CEO of STAAR Surgical.
“EVO ICL is the next logical step in refractive innovation with
clear differentiators in patient outcomes and satisfaction. Our
lens-based technology is ushering in the next generation of vision
correction by helping to free patients from the struggle of daily
contacts and eyeglasses.”
EVO ICL is an implantable lens designed to correct a wide range
of vision correction needs, including myopia with and without
astigmatism, through a minimally invasive procedure. The EVO ICL
lens is implanted between the iris (the colored part of the eye)
and the natural crystalline lens in a quick and safe 20-30 minute
procedure. It’s biocompatible and does not remove corneal tissue,
so it works with the natural eye, and the lens implant is removable
by a surgeon, if desired. Myopia (nearsightedness) is the most
common refractive visual error and is a global epidemic that is
expected to impact over half the world’s population by 2050.2
1 EVO ICL accounts for approximately 2.5 million of the 3
million total ICLs sold. 2 Ophthalmology 2016;123:1036-1042 © 2016
by the American Academy of Ophthalmology.
About STAAR Surgical
STAAR, which has been dedicated solely to ophthalmic surgery for
over 40 years, designs, develops, manufactures and markets
implantable lenses for the eye. These lenses are intended to
provide visual freedom for patients, lessening or eliminating the
reliance on glasses or contact lenses. All of these lenses are
foldable, which permits the surgeon to insert them through a small
incision. STAAR’s lens used in refractive surgery is called an
Implantable Collamer® Lens or “ICL,” which includes the EVO ICL™
product line. More than 3,000,000 ICLs have been sold to date and
STAAR markets these lenses in over 75 countries. To learn more
about the ICL go to: EVOICL.com. Headquartered in Lake Forest, CA,
the company operates manufacturing and packaging facilities in
Aliso Viejo, CA, Monrovia, CA, and Nidau, Switzerland. For more
information, please visit the Company’s website at
www.staar.com.
Important Safety Information for EVO ICL
The EVO Visian ICL lens is intended to correct/reduce
nearsightedness between -3.0 D up to -20.0 D and treat astigmatism
from 1.0 D to 4.0 D. If you have nearsightedness within these
ranges, EVO Visian ICL surgery may improve your distance vision
without eyeglasses or contact lenses. Because the EVO Visian ICL
corrects for distance vision, it does not eliminate the need for
reading glasses, you may require them at some point, even if you
have never worn them before. Since implantation of the EVO Visian
ICL is a surgical procedure, before considering EVO Visian ICL
surgery you should have a complete eye examination and talk with
your eye care professional about EVO Visian ICL surgery, especially
the potential benefits, risks, and complications. You should
discuss the time needed for healing after surgery. Complications,
although rare, may include need for additional surgical procedures,
inflammation, loss of cells from the back surface of the cornea,
increase in eye pressure, and cataracts. You should NOT have EVO
Visian ICL surgery if your doctor determines that 1) the shape of
your eye is not appropriate, 2) you do not meet the minimum
endothelial cell density for your age at the time of implantation,
3) you have moderate to severe glaucoma, 4) your vision is not
stable; or 5) if you are pregnant or nursing.
For additional information with potential benefits, risks and
complications please visit evoicl.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240318771746/en/
Investors & Media Brian Moore Vice President,
Investor Relations and Corporate Development (626) 303-7902, Ext.
3023 bmoore@staar.com
STAAR Surgical (NASDAQ:STAA)
Historical Stock Chart
From Jul 2024 to Aug 2024
STAAR Surgical (NASDAQ:STAA)
Historical Stock Chart
From Aug 2023 to Aug 2024